ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

NCAB working Group Is Not Subject To Open Meetings Law, NCI Official Says

December 9, 1994

In Brief: Vicent Bono Retires As Investigational Drugs Branch Chief; Weiss to Leave For Walter Reed

January 9, 1981

Porter Softens Proposal To require SBIR Scores To Match R01s

July 26, 1996

FDA Advisors Okay DDC For AIDS Treatment In Comb With AZT

May 8, 1992

Patient Satisfaction Was Crucial In ODAC Review Of Panretin

November 27, 1998

FDA Approves Bexxar For Non-Hodgkin’s Lymphoma

June 27, 2003